

July 29, 2024

The Secretary,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
C/1 G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
**(Scrip Code: THYROCARE)**

The Secretary,  
Listing Department,  
BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001  
**(Scrip Code: 539871)**

Dear Sir/Madam,

**Subject: Completion of Business Transfer Agreement with Polo Labs Private Limited.**

This in reference to our letter dated July 02, 2024, wherein the Company had intimated to the Stock Exchanges regarding execution of Business Transfer Agreement with Polo Labs Private Limited (“**Polo**”) for acquiring Polo’s diagnostic and pathological services business (including without limitation, the equipment(s), assets, intellectual property rights, brands, clients, franchise business), as a going concern (on a slump sale basis) which was subject to fulfilment of the Conditions Precedent as set out in the Business Transfer Agreement (“**BTA**”).

We would like to now inform that, the Company has completed the acquisition of the diagnostic and pathological services business of Polo on July 29, 2024 (“**Closing date**”) at 1.05 PM in terms of the said BTA and commenced the relevant operations on a going-concern basis w.e.f. July 29, 2024.

This is for your information and records.

Yours Faithfully,  
For Thyrocare Technologies Limited

Ramjee Dorai  
Company Secretary and Compliance officer